Health Care Equipment & Services

Pulse Biosciences CTO’s 100,000‑unit RSU grant signals executive confidence, talent retention and potential share‑price growth for investors.

Insider buying surge at PAVmed: CEO’s 350k‑share grant, 1.4m shares bought by execs, signals confidence ahead of new PortIO device and Octeris imaging launch.

HeartFlow’s AI‑driven coronary analysis platform delivers precise, non‑invasive CTA‑based hemodynamic insights, cutting MACE risk, enhancing decision‑making, and gaining global regulatory approval.

Insider buying at PAVmed shows executives betting on new products and strategic hires, signaling confidence in a potential rebound despite recent volatility.

Insightful look at Cigna’s insider filings, strategic health‑care moves and potential undervaluation – a must‑read for investors eyeing the next earnings cycle.

Priest Brady Patrick’s RSU purchase shows Clover Health’s leadership shifts to long‑term Medicare‑advantage focus, signaling confidence amid a steep 46% stock decline.

Discover how PAVmed’s insider grants and new PortIO device promise a turnaround, aligning exec incentives with long‑term growth and potential upside.

NeoGenomics insider buying, defense partnership, and FDA battery approval reveal a dual‑growth strategy poised to boost diagnostics and defense revenue—key insights for investors.

Discover how Clover Health’s CEO zero‑cost RSU purchase signals long‑term confidence in its Medicare Advantage strategy and what that means for investors amid regulatory and market shifts.

Insightful analysis of Sight Sciences insider sales shows tax‑covering transactions amid a 12% price drop, but the upcoming ASCRS 2026 presentation could spark a rebound and shift investor sentiment.